|
1.
|
|
10 p, 1.0 MB |
Complications of Autologous Stem Cell Transplantation in Multiple Myeloma : Results from the CALM Study
/
Waszczuk-Gajda, A. (University Clinical Centre-The Medical University of Warsaw) ;
Penack, O. (Charité - Universitätsmedizin Berlin) ;
Sbianchi, G. (Tor Vergata University) ;
Koster, L. (EBMT Data Office Leiden) ;
Blaise, D. (Institut Paoli Calmettes) ;
Reményi, P. (Dél-Pesti Centrumkórház) ;
Russell, N. (Nottingham University) ;
Ljungman, P. (Karolinska Institute) ;
Trneny, M. (University Hospital) ;
Mayer, J. (University Hospital Brno (República Txeca)) ;
Iacobelli, S. (Tor Vergata University) ;
Kobbe, G. (Heinrich Heine Universitaet) ;
Scheid, C. (University of Cologne) ;
Apperley, Jane (Imperial College) ;
Touzeau, C. (CHU Nantes) ;
Lenhoff, S. (Skanes University Hospital) ;
Jantunen, E. (Kuopio University Hospital) ;
Anagnostopoulos, Achilles (George Papanicolaou General Hospital) ;
Paris, L. (SST Papa Giovanni XXIII) ;
Browne, P. (Hope Directorate) ;
Thieblemont, C. (Hôpital St. Louis) ;
Schaap, N. (Radboud University Medical Centre) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Yakoub-Agha, I. (CHU de Lille) ;
Garderet, L. (Hôpital Pitié Salpetrière) ;
Styczynski, J. (Collegium Medicum UMK) ;
Schoemans, H. (KU Leuven-University of Leuven) ;
Moiseev, I. (Pavlov University) ;
Duarte, R. F. (Hospital Universitario Puerta de Hierro Majadahonda) ;
Peric, Z. (University of Zagreb) ;
Montoto, S. (St Bartholomew's Hospital) ;
van Biezen, A. (EBMT Data Office Leiden) ;
Mikulska, M. (IRC CS Ospedale Policlinico San Martino) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital Center and Research) ;
Ruutu, T. (Helsinki University Hospital) ;
Kröger, N. (University Hospital Eppendorf) ;
Morris, C. (Belfast City Hospital) ;
Koenecke, C. (Hannover Medical School) ;
Schoenland, S. (Heidelberg University Hospital) ;
Basak, G.W. (University Clinical Centre-The Medical University of Warsaw) ;
Universitat Autònoma de Barcelona
Background: The main goal of this post hoc analysis of the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study was to evaluate the rate of short-and long-term infectious and non-infectious complications occurring after ASCT in patients with multiple myeloma (MM). [...]
2022 -  10.3390/jcm11123541
Journal of clinical medicine, Vol. 11 Núm. 12 (6-2 2022) , p. 3541
|
|
|
2.
|
|
9 p, 484.1 KB |
Classification of suicidal thoughts and behaviour in children : results from penalised logistic regression analyses in the Adolescent Brain Cognitive Development study
/
Van Velzen, L.S. (University of Melbourne) ;
Toenders, Y.J. (Orygen) ;
Avila-Parcet, Aina (Institut d'Investigació Biomèdica Sant Pau) ;
Dinga, R. (Radboud University) ;
Rabinowitz, J.A. (Johns Hopkins University) ;
Campos, A.I. (The University of Queensland) ;
Jahanshad, N. (University of Southern California) ;
Rentería, M.E. (The University of Queensland) ;
Schmaal, L. (Orygen) ;
Universitat Autònoma de Barcelona
Despite efforts to predict suicide risk in children, the ability to reliably identify who will engage in suicide thoughts or behaviours has remained unsuccessful. Aims We apply a novel machine-learning approach and examine whether children with suicide thoughts or behaviours could be differentiated from children without suicide thoughts or behaviours based on a combination of traditional (sociodemographic, physical health, social-environmental, clinical psychiatric) risk factors, but also more novel risk factors (cognitive, neuroimaging and genetic characteristics). [...]
2022 - 10.1192/bjp.2022.7
The British journal of psychiatry, Vol. 220 Núm. 4 (february 2022) , p. 210-218
|
|
|
3.
|
|
9 p, 1.0 MB |
Lactate is associated with mortality in very old intensive care patients suffering from COVID-19 : results from an international observational study of 2860 patients
/
Bruno, Raphael Romano (Heinrich-Heine-University Duesseldorf) ;
Wernly, Bernhard (Paracelsus Medical University) ;
Flaatten, Hans (Haukeland University Hospital (Bergen, Noruega)) ;
Fjølner, Jesper (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Artigas Raventós, Antoni (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Bollen Pinto, Bernardo (Geneva University Hospitals) ;
Schefold, Joerg C. (University of Bern) ;
Binnebössel, Stephan (Heinrich-Heine-University Duesseldorf) ;
Baldia, Philipp Heinrich (Heinrich-Heine-University Duesseldorf) ;
Kelm, Malte (Heinrich-Heine-University Duesseldorf) ;
Beil, Michael (Hebrew University of Jerusalem) ;
Sigal, Sivri (Hebrew University of Jerusalem) ;
van Heerden, Peter Vernon (Hebrew University of Jerusalem) ;
Szczeklik, Wojciech (Jagiellonian University Medical College) ;
Elhadi, Muhammed (University of Tripoli) ;
Joannidis, Michael (Medical University Innsbruck) ;
Oeyen, Sandra (Universitair Ziekenhuis Gent) ;
Zafeiridis, Tilemachos (General University Hospital of Larissa (Grècia)) ;
Wollborn, Jakob (Brigham and Women's Hospital (Boston, Estats Units d'Amèrica)) ;
Arche Banzo, Maria José (Hospital Clínico Universitario Lozano Blesa) ;
Fuest, Kristina (Technical University of Munich) ;
Marsh, Brian (Mater Misericordiae University Hospital) ;
Andersen, Finn H. (Norwegian University of Science and Technology) ;
Moreno, Rui (Centro Hospitalar Universitário de Lisboa Central) ;
Leaver, Susannah (St George'S University Hospitals NHS Foundation Trust) ;
Boumendil, Ariane (Hôpital Saint-Antoine) ;
De Lange, Dylan W. (University Utrecht) ;
Guidet, Bertrand (Hôpital Saint-Antoine) ;
Jung, Christian (Heinrich-Heine-University Duesseldorf) ;
Universitat Autònoma de Barcelona
Lactate is an established prognosticator in critical care. However, there still is insufficient evidence about its role in predicting outcome in COVID-19. This is of particular concern in older patients who have been mostly affected during the initial surge in 2020. [...]
2021 - 10.1186/s13613-021-00911-8
Annals of Intensive Care, Vol. 11 (august 2021)
|
|
|
4.
|
|
11 p, 4.4 MB |
Culture expansion of CAR T cells results in aberrant DNA methylation that is associated with adverse clinical outcome
/
Salz, Lucia (RWTH Aachen University Medical School, Germany) ;
Seitz, Alexander (Miltenyi Biotec B.V. & Co. KG, Gladbach, Germany) ;
Schäfer, Daniel (Miltenyi Biotec B.V. & Co. KG, Gladbach, Germany) ;
Franzen, Julia (RWTH Aachen University Medical School, Germany) ;
Holzer, Tatjana (Miltenyi Biotec B.V. & Co. KG, Gladbach, Germany) ;
García-Prieto, Carlos A (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bürger, Iris (Miltenyi Biotec B.V. & Co. KG, Gladbach, Germany) ;
Hardt, Olaf (Miltenyi Biotec B.V. & Co. KG, Gladbach, Germany) ;
Esteller, Manel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Wagner, Wolfgang (RWTH Aachen University Medical School, Germany)
Chimeric antigen receptor (CAR) T cells provide new perspectives for treatment of hematological malignancies. Manufacturing of these cellular products includes culture expansion procedures, which may affect cellular integrity and therapeutic outcome. [...]
2023 - 10.1038/s41375-023-01966-1
Leukemia, Vol. 37 Núm. 9 (july 2023) , p. 1868-1878
|
|
|
5.
|
|
10 p, 3.3 MB |
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia : results of the BURKIMAB14 trial
/
Ribera, Josep Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Morgades, Mireia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Garcia-Calduch, Olga (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sirvent, Maialen (Hospital Universitario de Donostia) ;
Buendia, Buenaventura (Hospital Universitario 12 de Octubre) ;
Cervera, Marta (Institut Catala d'Oncologia-Hospital Joan XXIII) ;
Luzardo, Hugo (Hospital Universitario de Gran Canaria Dr. Negrin) ;
Hernandez-Rivas, Jesus Maria (Hospital Universitario de Salamanca) ;
Sitges, Marta (Hospital Universitari de Girona Doctor Josep Trueta) ;
Garcia-Cadenas, Irene (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Abrisqueta, Pau (Hospital Universitari Vall d'Hebron) ;
Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ;
Bastos-Oreiro, Mariana (Hospital General Universitario Gregorio Marañón) ;
De Llano, Maria Paz Queipo (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Bravo, Pilar (Hospital Universitario de Fuenlabrada. Madrid) ;
Torrent, Anna (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Herrera, Pilar (Hospital Universitario Ramon y Cajal) ;
Garcia-Guinon, Antonni (Hospital Universitari Arnau de Vilanova) ;
Vall-Llovera, Ferran (Hospital Universitari MútuaTerrassa) ;
Serrano, Josefina (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Terol, Maria José (Hospital Clinico Universitario de Valencia) ;
Bergua, Juan Miguel (Hospital San Pedro de Alcántara) ;
Garcia-Noblejas, Ana (Hospital Universitario de La Princesa) ;
Barrenetxea, Cristina (Hospital Universitario Basurto) ;
Llorente, Laura (Hospital Universitario HM Sanchinarro (Madrid)) ;
Garcia-Belmonte, Daniel (Hospital Universitario La Zarzuela) ;
Gimeno, Eva (Hospital del Mar (Barcelona, Catalunya)) ;
Cladera, Antonia (Hospital Universitari Son Llatzer) ;
Mercadal, Santiago (Institut Català d'Oncologia) ;
Sancho, Juan Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
High dose-intensive or infusional intermediate-dose immunochemotherapy is highly effective treatment for Burkitt lymphoma irrespective of human immunodeficiency virus (HIV) infection. However, toxicities of these regimens are relevant, especially in older adults and elderly patients. [...]
2024 - 10.3324/haematol.2023.283342
Haematologica, Vol. 109 Núm. 2 (january 2024) , p. 543-552
|
|
|
6.
|
|
8 p, 715.4 KB |
Head and neck cancers survival in Europe, Taiwan, and Japan : results from RARECAREnet Asia based on a privacy-preserving federated infrastructure
/
Botta, Laura (Department of Epidemiology and Data Science. Fondazione IRCCS Istituto Nazionale dei Tumori) ;
Matsuda, Tomohiro (Insititute of Cancer Control. National Cancer Center (Japò)) ;
Charvat, Hadrien (National Cancer Center (Japò)) ;
Chiang, Chung-Ju (Taiwan Cancer Registry Center) ;
Lee, Wen-Chung (Taiwan Cancer Registry Center) ;
van Gestel, Anna Jacoba (Department of Research & Development. Netherlands Comprehensive Cancer Organisation) ;
Martin, Frank (Department of Research & Development. Netherlands Comprehensive Cancer Organisation) ;
Geleijnse, Gijs (Department of Research & Development. Netherlands Comprehensive Cancer Organisation) ;
Cellamare, Mattheo (Department of Research & Development. Netherlands Comprehensive Cancer Organisation) ;
Bonfarnuzzo, Simone (Department of Epidemiology and Data Science. Fondazione IRCCS Istituto Nazionale dei Tumori) ;
Marcos-Gragera, Rafael (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Guevara, Marcela (Instituto de Investigación Sanitaria de Navarra) ;
Mousavi, Mohsen (East Switzerland Cancer Registry) ;
Craig, Stefano (Queen's University Belfast) ;
Rodrigues, Jessica (Porto Comprehensive Cancer Centre (Portugal)) ;
Rubió-Casadevall, Jordi (Institut de Recerca Biomèdica de Lleida) ;
Licitra, Lisa (Department of Oncology and Hemato-Oncology. University of Milan) ;
Cavalieri, Stephanie (Department of Oncology and Hemato-Oncology. University of Milan) ;
Resteghini, Carlo (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano) ;
Gatta, Gemma (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano) ;
Trama, Annalisa (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano)
Background: The head and neck cancers (HNCs) incidence differs between Europe and East Asia. Our objective was to determine whether survival of HNC also differs between European and Asian countries. [...]
2023 - 10.3389/fonc.2023.1219111
Frontiers in Oncology, Vol. 13 (2023) , p. 1219111
|
|
|
7.
|
|
6 p, 559.6 KB |
Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients : final results of the Spanish BOC HIV-HCV Study
/
Laguno Centeno, Montserrat (Hospital Clínic i Provincial de Barcelona) ;
Von Wichmann, M.A. (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Van den Eynde, E. (Hospital Universitari de Bellvitge) ;
Navarro, J. (Hospital Universitari Vall d'Hebron) ;
Cifuentes, C. (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Murillas, J. (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Veloso, S. (Hospital Universitari Joan XXIII de Tarragona) ;
Martínez-Rebollar, M. (Hospital Clínic i Provincial de Barcelona) ;
Guardiola Tey, Jose Maria (Institut d'Investigació Biomèdica Sant Pau) ;
Jou, A. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Gómez-Sirvent, J.L. (Hospital Universitario de Canarias (La Laguna)) ;
Cervantes, Manuel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Pineda, J.A. (Hospital Universitario Virgen de Valme (Sevilla, Andalusia)) ;
López-Calvo, S. (Complejo Hospitalario Universitario de A Coruña) ;
Carrero, A. (Hospital General Universitario Gregorio Marañón) ;
Montes, M.L. (Hospital Universitario La Paz (Madrid)) ;
Deig, E. (Hospital General de Granollers) ;
Tapiz, A. (Fundació Althaia) ;
Ruiz-Mesa, J.D. (Hospital Regional) ;
Cruceta, A. (Hospital Clínic i Provincial de Barcelona) ;
de Lazzari, E. (Hospital Clínic i Provincial de Barcelona) ;
Mallolas Masferrer, Josep (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC + pegylated interferon-α2a/ribavirin (PEG-IFN/RBV) in the retreatment of HIV-HCV co-infected patients with HCV genotype 1. [...]
2016 - 10.1016/j.ijid.2016.10.028
International journal of infectious diseases, Vol. 53 (january 2016) , p. 46-51
|
|
|
8.
|
|
9 p, 603.3 KB |
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma : Results From the Phase II MajesTEC-1 Study
/
Martin, Thomas G. (University of California San Francisco, USA) ;
Moreau, Philippe (University Hospital Hôtel-Dieu, Nantes, France) ;
Usmani, Saad Z. (Levine Cancer Institute/Atrium Health, Charlotte, NC) ;
Garfall, Alfred (University of Pennsylvania, Philadelphia, PA) ;
Mateos, M. V (Hospital Universitario de Salamanca) ;
San-Miguel, Jesús F. (Clínica Universidad de Navarra) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Nooka, Ajay K. (Emory University, Atlanta, GA) ;
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ;
Chari, Ajay (Mount Sinai School of Medicine, New York, USA) ;
Karlin, Lionel (Centre Hospitalier Lyon Sud, Pierre-Bénite, France) ;
Krishnan, Amrita (City of Hope National Medical Center (Duarte, Estats Units d'Amèrica)) ;
Bahlis, Nizar (University of Calgary, Canada) ;
Popat, Rakesh (University College London) ;
Besemer, Britta (University of Tuebingen, Tuebingen, Germany) ;
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ;
Delforge, Michel (Universitaire Ziekenhuizen Leuven, Belgium) ;
Trancucci, Danielle (Janssen Research & Development, Raritan, NJ) ;
Pei, Lixia (Janssen Research & Development, Raritan, NJ) ;
Kobos, Rachel (Janssen Research & Development, Raritan, NJ) ;
Fastenau, John (Janssen Research & Development, Raritan, NJ) ;
Gries, Katharine S. (Janssen Research & Development, Raritan, NJ) ;
van de Donk, Niels W.C.J. (Amsterdam University Medical Center, Vrije Universiteit Amsterdam, The Netherlands)
Introduction: Patients with relapsed or refractory multiple myeloma (RRMM) report significantly lower HRQoL compared with patients with newly diagnosed MM and experience further deterioration in HRQoL with each relapse and subsequent treatment. [...]
2023 - 10.1016/j.clml.2023.11.001
Clinical Lymphoma, Myeloma & Leukemia, 2023
|
|
|
9.
|
|
9 p, 821.4 KB |
Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma : Final Results of a Randomized Phase III Study
/
Kwak, Larry W. (Comprehensive Cancer Center, Duarte) ;
Sancho, Juan Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cho, Seok Goo (The Catholic University of Korea, Seoul, South Korea) ;
Nakazawa, Hideyuki (Shinshu University School of Medicine, Nagano, Japan) ;
Suzumiya, Junji (Shimane University Hospital, Innovative Cancer Center/Oncology-Hematology, Izumo, Japan) ;
Tumyan, Gayane (Division of Hematology and Bone Marrow Transplantation, Blokhin Russian Cancer) ;
Kim, Jin Seok (Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea) ;
Menne, Tobias (Newcastle University, UK) ;
Mariz, José (Instituto Português de Oncología do Porto) ;
Ilyin, Nikolai (Ministry of Health of the Russian Federation) ;
Jurczak, Wojciech (Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland) ;
Lopez Martinez, Aurelio (Hospital Arnau de Vilanova (València)) ;
Samoilova, Olga (Nizhniy Novgorod Region Clinical Hospital, Nizhniy Novgorod, Russia) ;
Zhavrid, Edvard (N. N. Alexandrov Republican Scientific and Practical Centre of Oncology and Medical Radiology, Belarus) ;
Yañez Ruiz, Eduardo (Universidad de la Frontera, Temuco, Chile) ;
Trneny, Marek (Charles University, Czech Republic) ;
Popplewell, Leslie (Toni Stephenson Lymphoma Cancer Center and Department of Hematology and Hematopoietic Cell Transplantation, Duarte, CA) ;
Ogura, Michinori (Kasugai Municipal Hospital, Aichi 486-8510, Japan.) ;
Kim, Wong Seog (Sungkyunkwan University School of Medicine, Seoul, South Korea) ;
Lee, Sang Joon (Celltrion. Inc, South Korea) ;
Kim, Sung Hyun (Celltrion. Inc, South Korea) ;
Ahn, Keum Young (Celltrion. Inc, South Korea) ;
Buske, Christian (University Hospital of Ulm, Germany)
Introduction: This double-blind, parallel-group, active-controlled phase III trial (NCT02260804) assessed CT-P10 and rituximab safety and efficacy in patients with previously untreated low-tumor-burden follicular lymphoma (LTBFL), including after a single switch from rituximab to CT-P10. [...]
2022 - 10.1016/j.clml.2021.08.005
Clinical Lymphoma, Myeloma & Leukemia, Vol. 22 Núm. 2 (february 2022) , p. 89-97
|
|
|
10.
|
|
9 p, 1.5 MB |
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma : updated results from IKEMA, a randomized Phase 3 study
/
Martin, Thomas (University of California at San Francisco, USA) ;
Dimopoulos, Meletios (University of Athens, Greece) ;
Mikhael, Joseph (Translational Genomics Research Institute. City of Hope Cancer Center, Phoenix, USA) ;
Yong, Kwee (University College Hospital, London, UK) ;
Capra, Marcelo (Centro Integrado de Hematologia e Oncologia. Hospital Mãe de Deus, Porto Alegre, Brazil) ;
Facon, Thierry (Lille University Hospital, France) ;
Hajek, Roman (University of Ostrava, Czech Republic) ;
Špička, Ivan (Department of Hematology. 1st Faculty of Medicine. Charles University and General Hospital, Prague, Czech Republic) ;
Baker, Ross (Murdoch University, Perth, Australia) ;
Kim, Kihyun (Sungkyunkwan University School of Medicine, Seoul, South Korea) ;
Martinez, Gracia (Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil) ;
Min, Chang-Ki (The Catholic University of Korea) ;
Pour, Ludek (University Hospital Brno (República Txeca)) ;
Leleu, Xavier (Service d'Hématologie et Thérapie Cellulaire. CHU and CIC Inserm, France) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Koh, Youngil (Seoul National University Hospital, Seoul, South Korea) ;
Suzuki, Kenshi (Japanese Red Cross Medical Center, Tokyo, Japan) ;
Casca, France (Ividata Life Science, Levallois-Perret, France) ;
Macé, Sandrine (Sanofi, R&D, Chilly-Mazarin, France) ;
Risse, Marie-Laure (Sanofi, R&D, Vitry-sur-Seine, France) ;
Moreau, Philippe (University Hospital Hôtel-Dieu, Nantes, France)
Longer-term outcomes with the anti-CD38 antibody isatuximab in combination with carfilzomib-dexamethasone (Isa-Kd) were evaluated in the randomized Phase 3 trial IKEMA (NCT03275285), in a prespecified, follow-up analysis of progression-free survival (PFS, primary study endpoint), final complete response (CR) using Hydrashift Isa immunofixation assay, minimal residual disease (MRD) negativity, and safety. [...]
2023 - 10.1038/s41408-023-00797-8
Blood Cancer Journal, Vol. 13 Núm. 1 (december 2023)
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
